agilon health (NYSE:AGL) Stock Price Up 5.3%

Shares of agilon health, inc. (NYSE:AGL - Get Free Report) rose 5.3% during trading on Tuesday . The stock traded as high as $5.40 and last traded at $5.40. Approximately 1,197,725 shares changed hands during trading, a decline of 79% from the average daily volume of 5,629,145 shares. The stock had previously closed at $5.13.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AGL. Benchmark cut their target price on shares of agilon health from $13.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th. Truist Financial reduced their price target on shares of agilon health from $10.00 to $7.50 and set a "hold" rating on the stock in a report on Thursday, February 29th. Royal Bank of Canada reduced their target price on shares of agilon health from $11.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, February 28th. Barclays assumed coverage on shares of agilon health in a research note on Wednesday, March 6th. They set an "underweight" rating and a $5.00 price target for the company. Finally, Jefferies Financial Group reaffirmed a "hold" rating and issued a $6.50 price target (down previously from $25.00) on shares of agilon health in a research report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $9.46.

agilon health Price Performance

The company has a fifty day moving average of $5.51 and a two-hundred day moving average of $9.29. The company has a quick ratio of 1.51, a current ratio of 1.51 and a debt-to-equity ratio of 0.05.

agilon health (NYSE:AGL - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.13). The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.02 billion. agilon health had a negative net margin of 5.76% and a negative return on equity of 21.74%. The company's quarterly revenue was up 71.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.14) EPS. Equities analysts expect that agilon health, inc. will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Checchi Capital Advisers LLC lifted its holdings in agilon health by 2.7% during the 1st quarter. Checchi Capital Advisers LLC now owns 264,457 shares of the company's stock worth $1,613,000 after purchasing an additional 6,920 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in agilon health during the 1st quarter worth approximately $65,000. Counterpoint Mutual Funds LLC acquired a new stake in agilon health during the 1st quarter worth approximately $421,000. Renaissance Capital LLC lifted its holdings in agilon health by 3.0% during the 1st quarter. Renaissance Capital LLC now owns 191,122 shares of the company's stock worth $1,166,000 after purchasing an additional 5,551 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in agilon health during the 4th quarter worth approximately $309,000.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.